RxDoctor Payments Data

Annabelle Vo

Psychiatric/Mental Health · Tacoma, WANPI 1699286336

Payments from drug & device makers

$1,811in general payments, 2019–2025

Across 46 payments — averaging $39.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$561
  • Otsuka America Pharmaceutical, Inc.$508
  • Johnson & Johnson$406
  • Alkermes, Inc.$234
  • Sunovion Pharmaceuticals Inc.$41
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$39
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$1,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,811 in reported general payments places this provider in the 85th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$57,128
Medicare patients
47
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$24,592
Lurasidone Hcl21$19,369
Quetiapine Fumarate151$3,906
Lisdexamfetamine Dimesylate12$2,897
Bupropion XlBupropion Hcl69$2,218
Atomoxetine Hcl11$1,902
Olanzapine52$1,720
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine59$1,239
Duloxetine Hcl33$843
Fluoxetine Hcl71$750
Clonazepam111$677
Lamotrigine66$602
Trazodone Hcl54$587
Mirtazapine39$570
Ziprasidone Hcl12$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$561$24,59212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →